Meeting
2024 ASCO Annual Meeting
Phase II study of pembrolizumab and lenvatinib in platinum sensitive recurrent ovarian cancer.
Authors
Smadar Bauer
Sheba Medical Center, Ramat Gan, Israel
Smadar Bauer , Akram Saad , Inbal Greenhouse , Anna Ruth Rapoport , Shir Shahar , Tania Barnatan , Ronit Satchi-Fainaro , Ronnie Shapira-Frommer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT04519151
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 5581)
DOI
10.1200/JCO.2024.42.16_suppl.5581
Abstract #
5581
Poster Bd #
452
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu
Poster
2023 ASCO Annual Meeting
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.
First Author: Gregory J. Riely
Poster
2022 ASCO Annual Meeting
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
First Author: Yuangyuan Zhao
Poster
2021 ASCO Annual Meeting
Anlotinib in combination with TQB2450 in patients with recurrent ovarian cancer (ACTION): A multicenter, single-arm, open-label, phase Ib trial.
First Author: Chunyan Lan